# A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis

> **NCT00713544** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 373 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** AZD5672
- **DRUG:** Etanercept
- **DRUG:** Placebo
- **DRUG:** AZD5672
- **DRUG:** AZD5672
- **DRUG:** AZD5672

## Key facts

- **NCT ID:** NCT00713544
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2011-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00713544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00713544, "A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00713544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*